USFDA gives nod to Lupin’s generic formulation for eye disorder treatment

This product will be manufactured at Lupin’s Pithampur facility in India.

Lupin share price today, Lupin share news
Lupin's shares are likely to remain in focus after the Indian generic drugmaker reported a stronger-than-expected rise in second-quarter profit. (Photo: Company Website)

Pharma major Lupin Limited on Wednesday announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Brimonidine Tartrate Ophthalmic Solution, 0.1%.

According to the company’s statement, the approval has been granted to market a generic equivalent of Alphagan® P Ophthalmic Solution, 0.1%, of AbbVie Inc. This product will be manufactured at Lupin’s Pithampur facility in India.

Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Brimonidine Tartrate Ophthalmic Solution (RLD AlphaganP) had an estimated annual sales of USD178.5 million in the U.S. (IQVIA MAT June 2024).

Get live Share Market updates, Stock Market Quotes, and the latest India News and business news on Financial Express. Download the Financial Express App for the latest finance news.

This article was first uploaded on August twenty-eight, twenty twenty-four, at fifty-five minutes past twelve in the night.
Market Data
Market Data